Cristina Morales

Dr. Cristina Morales

The Francis Crick Institute
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CMCristina Morales
Cristina Morales
MWMary Y. Wu
Mary Y. Wu
SHSebastijan Hobor
Sebastijan Hobor
EWElanor N. Wainwright
Elanor N. Wainwright
MMMatthew J. Martin
Matthew J. Martin
PSPaola Scaffidi
Paola Scaffidi
Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through inhibition of stem cell-related signaling pathways has proven challenging. Here, we show that cancer cells can be selectively deprived of self-renewal ability by interfering with their epigenetic state. Re-expression of histone H1.0, a tumor-suppressive factor that inhibits cancer cell self-renewal in many cancer types, can be broadly induced by the clinically well-tolerated compound Quisinostat. Through H1.0, Quisinostat inhibits cancer cell self-renewal and halts tumor maintenance without affecting normal stem cell function. Quisinostat also hinders expansion of cells surviving targeted therapy, independently of the cancer types and the resistance mechanism, and inhibits disease relapse in mouse models of lung cancer. Our results identify H1.0 as a major mediator of Quisinostat’s antitumor effect and suggest that sequential administration of targeted therapy and Quisinostat may be a broadly applicable strategy to induce a prolonged response in patients.

19 March 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
TMThaidy Moreno
Thaidy Moreno
BMBeatriz Monterde
Beatriz Monterde
LGLaura González-Silva
Laura González-Silva
IBIsabel Betancor-Fernández
Isabel Betancor-Fernández
CRCarlos Revilla
Carlos Revilla
IVIgnacio Varela
Ignacio Varela

9 April 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JMJosep Monserrat
Josep Monserrat
CMCristina Morales
Cristina Morales
LRLouise Richardson
Louise Richardson
TWThomas Stuart Wilson
Thomas Stuart Wilson
HPHarshil Patel
Harshil Patel
PSPaola Scaffidi
Paola Scaffidi

Verified
Journal Article
Open access
PDF file
Roberta NoberiniRoberta Noberini
Roberta Noberini
CMCristina Morales
Cristina Morales
ESEvelyn Oliva Savoia
Evelyn Oliva Savoia
SBStefania Brandini
Stefania Brandini
MJMaria Giovanna Jodice
Maria Giovanna Jodice
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
Epigenetic aberrations have been recognized as important contributors to cancer onset and development, and increasing evidence suggests that linker histone H1 variants may serve as biomarkers useful for patient stratification, as well as play an important role as drivers in cancer. Although traditionally histone H1 levels have been studied using antibody-based methods and RNA expression, these approaches suffer from limitations. Mass spectrometry (MS)-based proteomics represents the ideal tool to accurately quantify relative changes in protein abundance within complex samples. In this study, we used a label-free quantification approach to simultaneously analyze all somatic histone H1 variants in clinical samples and verified its applicability to laser micro-dissected tissue areas containing as low as 1000 cells. We then applied it to breast cancer patient samples, identifying differences in linker histone variants patters in primary triple-negative breast tumors with and without relapse after chemotherapy. This study highlights how label-free quantitation by MS is a valuable option to accurately quantitate histone H1 levels in different types of clinical samples, including very low-abundance patient tissues.

10 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TMThaidy Moreno
Thaidy Moreno
LGLaura González-Silva
Laura González-Silva
BMBeatriz Monterde
Beatriz Monterde
IBIsabel Betancor-Fernández
Isabel Betancor-Fernández
CRCarlos Revilla
Carlos Revilla
IVIgnacio Varela
Ignacio Varela
The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. Last decade’s research has evidenced a clear role of chromatin structure in cancer development and several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown.In this study, we have performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure, as well as functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor development.We have identified ARID2 production loss in 20% of lung cancer patients. Additionally, we have shown that ARID2-deficiency provokes profound chromatin structural changes, alters the transcriptional programme and impairs DNA repair which bolster the proliferative and metastatic potential of the cells both in vitro and in vivo. Moreover, we have demonstrated that ARID2 deficiency significantly affects the sensitivity of the cells to PARP inhibition.All these results support that ARID2 is a bona-fide tumor suppressor gene in lung cancer that might be exploited therapeutically.